Skip to content

US · JANX · BIOTECHNOLOGY

Janux Therapeutics, Inc. (JANX) intrinsic value and stock valuation

$10.08as of 2026-11-21 · Mkt cap 975.75M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Janux Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values JANX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from JANX’s statements →

Janux Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 januxrx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$10M
20192025
Net income
-$-113.62M
20192025
Free cash flow
-$-83.28M
20192025
Total equity
$956.8M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$10M$10.6M$8.08M$8.61M$3.64M
Operating income-$-157.67M-$-98.85M-$-72.98M-$-67.09M-$-32.93M
Net income-$-113.62M-$-68.99M-$-58.29M-$-63.06M-$-32.67M
EPSd-$-1.83M-$-1.28M-$-1.32M-$-1.52M-$-792.19K
Operating cash flow-$-82.23M-$-43.81M-$-50.58M-$-42.92M-$-16.98M
Capital expenditure-$-1.04M-$-360K-$-1.85M-$-6.45M-$-1.48M
Free cash flow-$-83.28M-$-44.17M-$-52.42M-$-49.37M-$-18.46M
Total assets$1.01B$1.06B$380.4M$364M$379.8M
Total debt$22.1M$23M$24.5M$25.3M$190K
Net debt-$-30.2M-$-407.58M$5.34M-$-26.12M-$-35.39M
Total equity$956.8M$1.02B$344.4M$320.7M$366.3M
Cash and short-term investments$966.6M$1.03B$344M$327M$375M
Income statement
20252024202320222021
Revenue$10M$10.6M$8.08M$8.61M$3.64M
Cost of revenue$2.03M$2.06M$1.96M$840K$26.2M
Gross profit$7.97M$8.53M$6.13M$7.77M-$-22.6M
Research and development expenses$125.9M$68.4M$54.9M$53.4M$26.2M
Selling, general and administrative expenses$41.8M$41.1M$26.1M$22.3M$10.3M
Other expenses-$-2.03M-$-2.06M-$-1.96M-$-840K-$-26.24M
Operating expenses$165.6M$107.4M$79.1M$74.9M$10.3M
Cost and expenses$167.7M$109.4M$81.1M$75.7M$36.6M
Interest income$44M$29.9M$14.7M$4.03M$260K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.03M$2.06M$1.96M$840K$110K
Ebitda-$-111.6M-$-66.93M-$-56.34M-$-62.22M-$-32.56M
Operating income-$-157.67M-$-98.85M-$-72.98M-$-67.09M-$-32.93M
Total other income/expenses, net$44M$29.9M$14.7M$4.03M$260K
Income before tax-$-113.62M-$-68.99M-$-58.29M-$-63.06M-$-32.67M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-113.62M-$-68.99M-$-58.29M-$-63.06M-$-32.67M
Weighted average shares outstanding$62M$53.8M$44M$41.5M$41.2M
Weighted average diluted shares outstanding$62M$53.8M$44M$41.5M$41.2M
Balance sheet
20252024202320222021
Cash and short-term investments$966.6M$1.03B$344M$327M$375M
Net receivables$6.43M$5.38M$2.16M$700K$200K
Inventory$0.00$0.00$0.00-$-700K$0.00
Total current assets$975.9M$1.03B$349.2M$332.4M$377M
Property, plant and equipment, net$22.3M$24.2M$27.8M$29.4M$1.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$820K$0.00$0.00$820K$0.00
Total non-current assets$31.6M$27.9M$31.2M$31.6M$2.81M
Total assets$1.01B$1.06B$380.4M$364M$379.8M
Accounts payable$4.97M$4.03M$2.42M$2.16M$2.46M
Short-term debt$2.39M$1.75M$1.52M$760K$190K
Deferred revenue$0.00$0.00$1.71M$5.41M$5.16M
Total current liabilities$25M$17.5M$13M$16.5M$12.8M
Long-term debt$19.8M$21.3M$23M$24.5M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$2.22M$700K
Total non-current liabilities$25.7M$21.3M$23M$26.8M$700K
Capital lease obligations$19.8M$23M$24.5M$25.3M$190K
Total liabilities$50.7M$38.7M$36.1M$43.3M$13.5M
Common stock$60K$60K$50K$40K$40K
Retained earnings-$-351.38M-$-237.76M-$-168.76M-$-110.47M-$-47.41M
Accumulated other comprehensive income (loss)$4.32M$2.16M$670K-$-1.53M-$-270K
Total equity$956.8M$1.02B$344.4M$320.7M$366.3M
Total investments$914.2M$594.6M$324.8M$275.6M$339.4M
Total debt$22.1M$23M$24.5M$25.3M$190K
Net debt-$-30.2M-$-407.58M$5.34M-$-26.12M-$-35.39M
Cash flow statement
20252024202320222021
Net income-$-113.62M-$-68.99M-$-58.29M-$-63.06M-$-32.67M
Depreciation and amortization$2.03M$2.06M$1.96M$840K$110K
Stock-based compensation$40.2M$33M$20M$17.2M$6.91M
Change in working capital$6.71M$690K-$-6.55M$4.28M$8.84M
Accounts receivable$0.00$0.00$0.00$0.00$8M
Inventory$0.00$0.00$0.00$0.00$830K
Accounts payable$980K$1.58M$280K-$-290K$2.14M
Net cash provided by operating activities-$-82.23M-$-43.81M-$-50.58M-$-42.92M-$-16.98M
Investments in property, plant and equipment-$-1.04M-$-360K-$-1.85M-$-6.45M-$-1.48M
Acquisitions, net$0.00$0.00$0.00-$-64.71M$339.5M
Net cash used for investing activities-$-300.98M-$-258.02M-$-41.19M$58.3M-$-340.96M
Common stock issued$5.29M$698.3M$56.5M$500K$204.2M
Common stock repurchased-$-350K$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.95M$713.2M$59.6M$500K$386.5M
Net change in cash-$-378.27M$411.4M-$-32.22M$15.8M$28.6M
Cash at end of period$53.2M$431.4M$20M$52.2M$36.4M
Operating cash flow-$-82.23M-$-43.81M-$-50.58M-$-42.92M-$-16.98M
Capital expenditure-$-1.04M-$-360K-$-1.85M-$-6.45M-$-1.48M
Free cash flow-$-83.28M-$-44.17M-$-52.42M-$-49.37M-$-18.46M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Janux Therapeutics, Inc.

        Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

        CEO
        David Alan Campbell
        Employees
        109
        Beta
        2.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Janux Therapeutics, Inc. (JANX)?

        Janux Therapeutics, Inc. (JANX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is JANX undervalued?

        JANX trades at a price of $10.08 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.